Jasper Therapeutics, Inc. (JSPR)
NASDAQ: JSPR · IEX Real-Time Price · USD
21.59
-1.62 (-6.98%)
At close: Apr 19, 2024, 4:00 PM
20.93
-0.66 (-3.06%)
After-hours: Apr 19, 2024, 6:53 PM EDT
Jasper Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Jasper Therapeutics stock have an average target of 64.79, with a low estimate of 40 and a high estimate of 80. The average target predicts an increase of 200.09% from the current stock price of 21.59.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for JSPR stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 4 | 4 | 4 | 4 | 6 | 7 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI Group | Evercore ISI Group | Buy Initiates $65 | Buy | Initiates | $65 | +201.07% | Apr 3, 2024 |
| RBC Capital | RBC Capital | Buy Initiates $70 | Buy | Initiates | $70 | +224.22% | Mar 28, 2024 |
| TD Cowen | TD Cowen | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Mar 18, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $80 | Buy | Maintains | $80 | +270.54% | Mar 7, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $60 | Buy | Reiterates | $60 | +177.91% | Oct 12, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
7.48M
EPS This Year
-5.07
from -6.18
EPS Next Year
-4.26
from -5.07
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | 46.2M | 10.5M | 67.9M | 190.5M |
| Avg | n/a | 7.5M | 2.6M | 32.9M | 185.0M |
| Low | n/a | n/a | n/a | 9.0M | 177.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 40.4% | 2,530.1% | 478.5% |
| Avg | - | - | -65.5% | 1,174.7% | 462.0% |
| Low | - | - | - | 249.3% | 439.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -4.01 | -3.81 | -3.78 | -0.43 | 0.43 |
| Avg | -5.07 | -4.26 | -5.54 | -0.42 | 0.42 |
| Low | -6.60 | -5.28 | -7.13 | -0.40 | 0.40 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.